Overview

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Status:
Completed

Trial end date:
2019-06-20

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Galapagos NV

Treatments:

Adalimumab
Methotrexate